Cynata only have to prove our MSCs are functionally equivalent to other ones and that we can actually scale as we claim.
The ideal position is they design and prove up the treatments, and Cynata industrialises them for scale.
Having Celularity say that is a massive endorsement of CYP and its technology.
Ann: Cyanta & Celularity Inc Execute MOU, page-9
Add CYP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $34.32M | |||
| Open | High | Low | Value | Volume |
| 19.0¢ | 19.0¢ | 18.5¢ | $7.059K | 37.62K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 58798 | 18.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 19.0¢ | 118880 | 1 |
View Market Depth
| Last trade - 16.10pm 17/09/2024 (20 minute delay) ? |
| CYP (ASX) Chart |